Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Orexigen Therapeutics Announces Webcast of Upcoming Presentation at the Cowen & Co. Annual Health Care Conference



Orexigen Therapeutics Announces Webcast of Upcoming Presentation at the Cowen
                     & Co. Annual Health Care Conference

PR Newswire

SAN DIEGO, Feb. 28, 2013

SAN DIEGO, Feb. 28, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq:
OREX) today announced that management will present a company overview at the
Cowen & Co. Annual Health Care Conference in Boston. The presentation is
scheduled for Monday, March 4, 2013 at 3:30 p.m. Eastern Time. To listen to
the live webcast or a replay of the presentation, please visit the Investor
Relations section of the Company's Web site at www.orexigen.com. A replay will
be available for 14 days after the event.

About Orexigen® Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the
treatment of obesity. The Company's lead product candidate is Contrave®, which
has completed Phase III clinical trials and for which a New Drug Application
has been submitted and reviewed by the FDA. The Company has also reached
agreement with the FDA on a Special Protocol Assessment for the Light Study,
the Contrave cardiovascular outcomes trial. The Company's other product
candidate, Empatic™, has completed Phase II clinical trials. Further
information about the Company can be found at www.orexigen.com.

Orexigen Contact:                                     Media Contact: 
McDavid Stilwell                                      Denise Powell
VP, Corporate Communications and Business Development WCG
(858) 875-8629                                        (510) 703-9491

SOURCE Orexigen Therapeutics, Inc.

Website: http://www.orexigen.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement